How do startup funding work?

Startup funding is the process of financing a new company so it can build a product, acquire customers, and grow—usually before it generates enough profit to fund itself. In practice, “funding” is a series of rounds (Seed, Series A, etc.) where you raise money using a specific instrument (equity, SAFE, convertible note, debt, grants), at a certain valuation, under a set of legal terms (a term sheet).

If you’re a technical/medical/scientific founder, the key mental model is simple: investors are buying a slice of a future outcome, and they price that slice based on risk. Early on, risk is high (no product, no traction), so investors demand either a lower price (lower valuation) or extra protections. As you prove things—working product, paying customers, repeatable growth—the risk drops and your company can raise at higher valuations with better terms.

The core mechanics: valuation, dilution, and “runway”

Three concepts explain 80% of how startup funding works:

• Valuation: the implied price of the company. In equity rounds you’ll hear pre-money (value before the new cash) and post-money (pre-money + new cash).
• Dilution: when you issue new shares to investors, existing owners’ percentage ownership goes down. This is normal; the goal is to own a smaller % of a much larger company.
• Runway: how many months you can operate before you run out of cash. Roughly runway = cash in bank / monthly net burn (burn = expenses minus revenue).

Example (simple math): You raise $2M at a $8M pre-money valuation. Post-money is $10M. The new investors own $2M/$10M = 20% of the company immediately after the round (before considering option pools; more on that below). Founders and earlier holders are diluted to 80% combined.

Most startups raise to buy 12–24 months of runway. Less than ~12 months can force you into fundraising again before you’ve hit meaningful milestones; much more than ~24 months can mean you raised too early (and diluted more than necessary). This varies by industry and sales cycle.

Funding stages: what changes from pre-seed to Series A and beyond

Rounds are labels for a company’s maturity. The exact names vary, but the investor question is consistent: “What risk has been removed since the last round?”

Pre-seed / Seed: prove the problem and early demand

At Seed, investors typically want evidence you’re solving a real problem for a specific customer. For many startups, that means:

• A clear ICP (Ideal Customer Profile): who buys, in what context, and why.
• Early traction: pilots, letters of intent (LOIs), waitlists, or initial revenue (quality matters more than quantity).
• A credible plan to reach a repeatable acquisition channel.

Seed rounds often use SAFEs (Simple Agreement for Future Equity) or convertible notes. These defer setting a valuation until a later priced round.

Series A: prove a repeatable growth engine

Series A investors usually want signs of product-market fit (PMF): customers consistently buy, stay, and get value. In B2B, they often look for a repeatable sales motion; in B2C, a scalable acquisition channel and retention.

Series A is commonly a priced equity round (you set a valuation and sell shares now). The company will also formalize governance (board seats, reporting) and tighten metrics.

Series B/C+: scale efficiently

Later rounds focus on scaling what works: expanding markets, hiring aggressively, and improving unit economics (how much profit you make per customer after variable costs). Terms can become more complex, but the core trade remains cash for ownership.

Common funding instruments (and when founders use each)

“Instrument” means the legal form of the investment. Here are the most common ones:

1) Equity (priced round)

Investors buy shares now at an agreed valuation. This is straightforward but requires more legal work and negotiation.

Good when: you have enough traction to justify a valuation and want clean ownership structure.

2) SAFE (future equity)

A SAFE is an agreement that converts into equity later, usually at the next priced round, with a benefit to early investors via:

• Valuation cap: maximum valuation at which the SAFE converts (better for investors if the company grows fast).
• Discount: converts at a reduced price vs. new investors.

Founder watch-out: SAFEs can hide dilution until later. A “post-money SAFE” makes dilution more explicit; either way, model the ownership outcomes before signing.

3) Convertible note (debt that converts)

A convertible note is a loan that typically converts into equity at the next round. It has an interest rate and a maturity date (when it technically comes due).

Good when: you need speed, but investors want more structure than a SAFE.

4) Venture debt / bank debt

Debt doesn’t directly dilute ownership, but it must be repaid and often includes covenants (rules) and sometimes warrants (small equity kicker). It’s usually used when you already have predictable revenue or strong backing.

5) Grants and non-dilutive funding

Non-dilutive means you don’t give up equity. Grants can be great for R&D-heavy startups, but timelines, reporting, and eligibility vary widely. Treat them as a parallel track, not your only plan.

Term sheets: the few terms that matter most

A term sheet is a summary of the deal economics and control terms. It’s not the full legal contract, but it drives it. Founders often fixate on valuation; experienced founders also focus on control and downside protections.

Key terms to understand:

• Option pool: shares reserved for employee equity. Often increased at a round, which can dilute founders. Ask whether the pool is calculated pre-money or post-money.
• Liquidation preference: who gets paid first if the company sells or shuts down. A common structure is “1x non-participating” (investor gets their money back first, then converts to common if that’s better). More aggressive preferences can heavily reduce founder outcomes in modest exits.
• Board composition: who controls major decisions. Early on, keep governance simple; avoid giving away control too early.
• Pro-rata rights: investor’s right to maintain their ownership % in future rounds.
• Vesting: founders’ shares typically vest over time (often 4 years with a 1-year cliff). This protects the company if a founder leaves early.

Practical rule: If you don’t understand a term, don’t “assume it’s standard.” Ask your lawyer and also ask, “What happens to founder ownership and payout in a low, medium, and high exit?” A simple table model can reveal surprises.

What investors are really underwriting (and how to prepare)

Investors are not only buying your product idea; they’re underwriting a risk-reduction plan. You’ll raise faster if you can clearly answer:

1. Market: Is the problem painful and frequent? Is the market big enough to support a venture-scale outcome?
2. Why you: Do you have unique insight, access, or capability (domain expertise, distribution, IP, clinical network, etc.)?
3. Traction: What proof exists today (revenue, retention, pilots, LOIs, usage)?
4. Go-to-market: How will you acquire customers predictably? (Sales cycle, pricing, channel, who signs.)
5. Economics: Do unit economics look like they can work at scale? Early numbers can be rough, but the logic must be sound.

Also understand the fundraising process itself: you’ll typically run a tight 4–8 week “raise” where you talk to many investors, build momentum, and aim for a lead investor who sets terms. Fundraising is a sales process; treat it like one (pipeline, follow-ups, clear next steps).

What to do next

1. Model dilution for 2–3 scenarios (e.g., raise $1M, $2M, $3M) including an option pool, so you know your ownership outcomes before negotiating.
2. Define your milestone-based raise: write the 3–5 concrete milestones this round buys (e.g., “10 paying customers,” “$X MRR,” “regulatory plan finalized,” “pilot converted to contract”).
3. Draft a one-page fundraise brief (problem, ICP, solution, traction, business model, go-to-market, team, ask) and use it to test clarity with smart peers.
4. Pressure-test your term sheet literacy using a checklist, then review any real offer with a startup lawyer before signing.
5. Build your investor pipeline: list 30–60 relevant investors, track outreach, and run weekly updates once you start meetings.

If you want structured help, try the /launchpad to organize your milestones and narrative, and use /finances to sanity-check runway and dilution.